BMT2

Across TCGA pan-cancer cohorts, BMT2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of BMT2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where BMT2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BMT2 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

KIRP, LIHC, and KIRC are the cancer types where BMT2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BMT2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	IV	+1.257	<.001	11	view →
LIHC	Female	II,III,IV	+0.827	<.001	7	view →
KIRC	Male	All	+0.353	<.001	7	view →
CHOL	Male	All	+1.880	<.001	5	view →
KICH	Female	All	−1.289	<.001	5	view →
THCA	Male	All	−0.441	<.001	5	view →
LUSC	All	All	+0.507	<.001	4	view →
HNSC	All	All	+0.308	.022	4	view →
LUAD	All	All	+0.354	<.001	3	view →
ESCA	All	All	+0.747	.005	2	view →
UCEC	All	All	−0.537	.009	2	view →
PRAD	All	All	−0.329	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

BMT2–KIRP

Open the KIRP breakdown →